Archive |
Xention & Ono Agreement Continues
Apr 2011
XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced today that it had extended its collaboration with Ono Pharmaceutical Co., Ltd. (“Ono”).
more...
Aushon Launches New SignaturePLUS System
Apr 2011
The SignaturePLUS system is designed to meet the cost and performance needs of researchers for accurate, reproducible, and reliable multiplex protein biomarker analysis across pre-clinical, clinical and diagnostics applications in all therapeutic areas.
more...
Almac Wins 2011 Business Accolade
Apr 2011
The Almac Group, headquartered in Craigavon Northern Ireland, is celebrating another highly impressive year after being named ‘Business of the Year’ (for the second time in 3 years), together with other significant accolades at the Northern Ireland business awards.
more...
VisualSonics New In Vivo Imaging Technology
Apr 2011
VisualSonics Inc., a leader in real time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., is demonstrating the Vevo® LAZR Photoacoustics Imaging system at the American Association of Cancer Research’s annual conference.
more...
Cancer Treatment Breakthrough
Apr 2011
Scientists from the School of Pharmacy at Queen’s University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural protein first discovered at QUB.
more...
Halo Genomics Signs Co-Marketing Agreement
Apr 2011
Halo Genomics proprietary Selector technology™ enables enrichment of regions of interest in the human genome for targeted resequencing applications.
more...
Qiagen Proposal To Acquire Cellestis Ltd
Apr 2011
QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately US$355 million in cash, providing QIAGEN with access to a novel “pre-molecular” technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
more...
Roche & NuGEN Develop Profiling Solution
Apr 2011
Roche and NuGEN Technologies to co-promote NuGEN’s Ovation® RNA-Seq System with the GS FLX and GS Junior Systems to enable whole transcriptome profiling with low abundance RNA samples.
more...
BioWa & Oxford Bio Enter Agreement
Apr 2011
BioWa, Inc. and Oxford BioTherapeutics Ltd (OBT) have entered into a license agreement to provide OBT with access to BioWa’s patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
more...
Cellular Dynamics Raises $30 Million
Apr 2011
Cellular Dynamics International, Inc. (CDI), the world’s only industrial manufacturer of human induced pluripotent stem cells (iPSCs) and tissue cells, has closed on a $30 million private equity round.
more...
Immatics to receive support from Pfizer
Apr 2011
Immatics biotechnologies GmbH, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.
more...
Plasticell launches 2nd generation Combicult
Oct 2010
Plasticell, the biotechnology company specialising in high throughput screening for stem cell differentiation, announces the launch of its second generation CombicultTM 10,000-plex screen capable of rapidly screening up to ten thousand cell culture media combinations.
more...
DuoCort & Recipharm Begin Collaboration
Oct 2010
DuoCort Pharma announces it has concluded an agreement with Recipharm under which Recipharm is set to scale-up the manufacturing of DuoCort’s tablets to commercial scale as DuoCort Pharma prepares for market entry with its orphan drug for the treatment of Addison’s disease.
more...
IBA Granted Filtracis Marketing Approval
Oct 2010
IBA Molecular, member of IBA group and global developer of next generation radiopharmaceuticals, announced today that it received approval to market Filtracis™ in France from the AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé) on September 28, 2010.
more...
Rockland Awarded Phase I SBIR Funding
Oct 2010
Rockland Immunochemicals Inc., today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.
more...
Human Virus Helps to Treat Cancer Patients
Oct 2010
A naturally-occurring harmless human virus given in combination with radiotherapy has shown significant goody in patients with wide cancer, equal to results of an early trial published online in the periodical Clinical Cancer Research.
more...
Massive boost for UK life sciences
Oct 2010
Coming hard on the heels of good news for life sciences from the Spending Review and £50 million from the Technology Strategy Board (TSB) for stratified medicine, two new initiatives were launched today by Universities and Science Minister David Willetts.
more...
Egg meets sperm: The female side of the story
Oct 2010
Researchers at Karolinska Institutet have been able to describe the 3D structure of a complete egg receptor that binds sperm at the beginning of fertilization. The results will lead to better understanding of infertility and may enable entirely new types of contraceptives.
more...
Ricerca Announces Senior Leadership
Oct 2010
Ricerca Biosciences, a preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the addition of William DeMaio, Ph.D., as senior director of the drug metabolism and pharmacokinetics (DMPK) department.
more...
Sigma Partners with Autism Speaks
Oct 2010
Sigma Life Science, services research business of Sigma-Aldrich, today announced a partnership between its SAGE Labs division and Autism Speaks to create genetically engineered knockout rats to aid identification of new therapeutic approaches for the treatment of autism.
more...
Celgene acquires Abraxis and Abraxane
Oct 2010
Celgene Corporation has completed its acquisition of Abraxis BioScience, Inc. The transaction adds Abraxane® to the company’s existing portfolio of leading cancer products and offers another significant scientific platform that may drive future development.
more...
Metabolon Develops Software Method
Oct 2010
Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the online publication of “Organization of GC/MS and LC/MS Metabolomics Data into Chemical Libraries” in the Journal of Cheminformatics.
more...
Rexahn Pharmaceuticals New Preclinical Data
Oct 2010
Rexahn Pharmaceuticals, Inc., announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.
more...
AbD Serotec selected as preferred supplier
Oct 2010
MorphoSys AG announced today that its research and diagnostic antibodies unit AbD Serotec has signed a two year contract for the supply of custom monoclonal antibodies with Research Councils UK Shared Services Centre Limited (RCUK SSC Ltd).
more...
Key to blood-brain barrier
Oct 2010
While the blood-brain barrier protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at Karolinska Institutet now present a potential solution to the problem.
more...
Biosearch Tech. Awarded Army SBIR Grant
Oct 2010
Biosearch Technologies, Inc., announced that the company has been awarded another Phase II Small Business Innovative Research (SBIR) grant from the Department of Defense (DoD).
more...
Almac Moves Clinical Tech. Business Unit
Oct 2010
Almac announced today that its Clinical Technologies division has successfully moved into the Almac Group’s new North American Headquarters.
more...
Kaluza 1.1 from Beckman Coulter
Oct 2010
Beckman Coulter's new flow cytometry analysis software, Kaluza 1.1, processes multicolor files of up to 10 million events and offers analytical speed that is much faster than the previous version and several hundred times faster than other commercially available software.
more...
SAW Instruments Launch Novel sam5 Biosensor
Oct 2010
SAW Instruments GmbH has launched its unique sam5 biosensor instrument for advanced real-time biomolecular interaction and kinetic studies, at Biotechnica, Hannover, 5-7 October.
more...
GSK 1st Singapore-based Academic Projects
Oct 2010
GlaxoSmithKline R&D [GSK] today announced the start of four new academic collaborations with Singapore-based scientists and GSK’s global drug discovery network as the first step in a longer term plan to seek alliances with scientific experts in the country.
more...
| This month's featured video |
BMG Labtech At SBS Conference
Apr 2011
BMG LABTECH, world leader in microplate reader technology, is proud to be a Bronze Sponsor of the SBS Conference 2011 in Orlando, Florida. Visit us at booth 807 and join us at our workshops to see latest innovations in microplate reading technology including the SPECTROstar Nano, which can instantly capture a full UV/Vis spectrum (220 – 1000 nm) in low volume samples, microplates and cuvettes.
more...
Thermo Fisher Scientific Introduces a Tailor-Made Peptide Library
Apr 2011
Thermo Fisher Scientific Inc., the world leader in serving science, today introduced Thermo Scientific PEPotec SRM, a custom peptide library that is designed for medium to high-throughput development of single-reaction monitoring assays.
more...
Accelerating Genomic Research and Personalized Medicine Conference
13-15 December
Hear from industry leaders within Pharmaceutical, Biotechnology, and Diagnostic organizations on translating meaningful data into a clinical setting and examining genomic technologies for guided patient management.
more...
GDDIS 2010
8-9 November
The Annual GDDIS is the leading R&D meeting for decision makers, scientific leaders and strategists. It is the only two day gathering dedicated to both real technology innovation & strategy across the entire R&D realm.
more...
Progress in the implementation of Label-Free Dectetion - part 1: cell-based assays
Fall 2008
Overall it remains unclear whether label-free will break into main stream cell-based lead discovery or will mostly fill the gaps that other technologies do less well?
more...
Natural product pharmaceuticals - the third generation
By Dr Melanie McCullagh
Compounds derived from natural products have made a big impact on the pharmaceutical industry. Of the 1,010 NCEs approved between January 1981 and June 2006, 43 were unaltered natural products (NPs) and a further 232 (23%) were second generation NP derivatives1.
more...
TECHNOLOGY, bane or bonanza for the pharmaceutical industry?
By Dr Stephen Naylor, Adam W. Culbertson and Dr Stephen J. Valentine
While the adoption of new technologies into the drug development process has often been seen as a panacea this article argues that, without a true understanding of the complexities how can we expect it to be the bonanza to the pharmaceutical industry and the cure for all its woes?
more...
The DEMING Approach to Quality
By John H. Van Drie
We explore the relevance to pharmaceutical research of the ideas of W. Edwards Deming, the statistician whose ideas on quality transformed the manufacturing sector of post-war Japan.
more...
Microwave-Assisted Orgainc Synthesis an Enabling Technology with Disruptive Potential.
Fall 2008
Since the original publications on the benefits of conducting organic reactions in a microwave by Gedye1 and Majetich2 in the mid-80s, the uptake of this technique was sluggish at best for the next 12-14 years.
more...
Recent Advances in HCS LaserR Scanning Cytometry
By Dr John Comley
Laser scanning cytometers have matured over the past decade to meet the needs of end-users for higher throughput cell analysis, to access to previously difficult applications and to keep pace with the diversity of new fluorophores, validated high content screening (HCS) assay kits and reagents now available.
more...
High Throughput Screening, High Content Screening, Primary and Stem Cells
By Dr Richard M. Eglen
Over the past decade, the use of cell-based assays has accelerated in modern drug discovery. Indeed, the majority of assays in either target validation or lead identification/optimisation all now employ cell-based technologies.
more...
Biologists Flirt with Models
By Gordon Webster
The enormous challenge posed by the complexity of biological systems represents a potential intellectual impasse to researchers and threatens to stall future progress in basic biology and healthcare.
more...
High content screening – the next challenge: effective data mining and exploration
By Dr Kurt Zingler and Dr Stephan Heyse
The use of high content screening within HTS is growing and with many past hurdles now overcome, the need for effective tools for data analysis is becoming paramount.
more...
Overview of Companion Diagnostics in the Pharmaceutical Industry
By Dr Stephen Naylor and Toby Cole
Current escalating costs of drug discovery, development and drug launch continue to concern the pharmaceutical sector. This has been compounded by the advent of personalised medicine and its associated demands for individualised products as well as the demise of the ‘blockbuster’ model.
more...
Biomarker signal definition
By Dr Gordon F. Kapke and Dr Nigel Brown
Due to the numerous challenges in the industry, pharmaceutical companies are examining all aspects of the drug development process and rebuilding theirassociated business models as necessary. more...
STEM CELLS for cellular therapy space
By Dr Enal S. Razvi and Dr Gary M. Oosta
This article explores the emerging market landscape vis-à-vis the use of stem cells as cellular therapeutics. For more than 40 years, hematopoietic stem cells have been utilised as cellular therapeutics in a number of malignant diseases as well as inborn genetic errors of metabolism.
more...
Reshaping the landscape of cancer drug discovery and development
By Dr Paolo Paoletti
The landscape of cancer drug discovery and development is shifting – adjusting and reshaping itself in response to the huge rush of scientific knowledge
more...
REAL-TIME PCR - where we are and where are we heading
By Dr Mikael Kubista
Quantitative real-time PCR is becoming mature technology for the quantification of nucleic acids. It is spreading wide outside its original use in the research laboratories, becoming preferred technology for a range of applications, many that require specialised solutions and adaptations. Integration with pre-analytical steps and post-processing operations are becoming key challenges.
more...
COMPOUND PROFILING size impact on primary screening libraries
By William Downey, Cindy Liu and Dr Jennifer Hartigan
A recent report examines the trends in utilisation of compound libraries, as well as the impact of profiling on the size of screening decks. The drivers for choosing between large or focused libraries may be different, but the ultimate goal remains the same: improve drug discovery.
more...